Vergleich

Human NKG2A / CD159a Protein, Fc Tag Europäischer Partner

ArtNr NKA-H526c-100ug
Hersteller ACROBiosystems
Menge 100 ug
Quantity options 100 ug 500 ug x 2
Kategorie
Typ Proteins Recombinant
Format Solid
Specific against Human (Homo sapiens)
Host HEK293
Konjugat/Tag Unconjugated, Fc
Purity 95%
Citations (1) Sun C, et al. Oncoimmunology. 2016. 6(1):e1264562. (2) McWilliams EM, et al. Oncoimmunology. 2016. 5(10). (3) van Montfoort N, et al. Cell. 2018. 175(7):1744-1755.
NCBI NP_002250.1
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias NKG2A,CD159a,KLRC1,NK cell receptor A
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Category
Protein
Manufacturer - Conjugate / Tag
N-Fc, Unconjugated
Shipping Temperature
RT
Storage Conditions
-20°C
Molecular Weight
42.5 kDa
Manufacturer - Format
Powder
Description
NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
Background
NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.
Molecule
NKG2A
Exp Region
Pro 94 - Leu 233
Characteristics
This protein carries a human IgG1 Fc tag at the N-terminus. The protein has a calculated MW of 42.5 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
1.0 EU per μg
Buffer
Tris with Glycine, Arginine and NaCl, pH7.5
Stability
● -20°C to -70°C for 12 months in lyophilized state
● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant
trehalose

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 ug
Lieferbar: In stock
lieferbar

Lieferung vsl. bis 19.02.2026 

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?